Aadi Q3 net loss $87.2M; FYARRO PDUFA Nov 26; cash $161.4M

Whitehawk Therapeutics, Inc.

2022-Q3 EPS reported -$19.37 revenue$120,000

FYARRO (nab-sirolimus) NDA under FDA priority review with PDUFA target Nov 26, 2021.
Ended Q3 with $161.4M cash; expected runway into 2024 post merger & $155M PIPE.
Net loss $87.2M for Q3, primarily from $74.2M non-cash impairment related to merger.
Appointed Brendan Delaney COO, Loretta Itri CMO (Q4), Scott Giacobello CFO (Nov 28).
Plan to initiate registrational trial in TSC1/TSC2 tumors by end 2021 or early 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.